Melangkah 1: Separate Identity Testing From Purity Data
Identity and purity are separate analytical questions, and a supplier that answers only one of them has answered neither. Identity asks what the material is: it requires specific, orthogonal confirmation such as mass spectrometry, LC-MS/MS, amino acid analysis, NMR, peptide mapping, or HPLC retention against a reference standard (USP reference standard work, 2023). Mass spectrometry separates molecules by mass-to-charge ratio and reports a molecular weight; LC-MS/MS adds a fragmentation step that reads sequence information. Purity is a different measurement entirely: it quantitates the target peptide relative to impurities and related substances, and says nothing about whether the target is the right molecule.
That gap is the failure mode worth naming. A compound can read 99% pure by HPLC and still be the wrong peptide, because a high purity figure is not evidence of identity. In BPC-157 purity testing, a clean chromatogram confirms that one species dominates the sample, not that the species is BPC-157.
Purity is calculated from the integrated peak area: target peak area divided by total integrated peak area, multiplied by 100. The convention assumes reversed-phase HPLC on a C18 column with UV detection at 220 nm, the wavelength where peptide bonds absorb (GenScript peptide quality documentation).
What to check: does the documentation package contain an identity method (MS, LC-MS/MS, or equivalent) reported separately from the purity method, or does it present a single purity percentage as the whole analytical story?
Toko =”https://molchanges.com/wp-content/uploads/2026/10/pub_20261002_013927_165_11203be2c7974a76b7f4d56fce8c9749.png”>
Melangkah 2: Read a Purity Claim for Its Method, Lot, Lab, and Date
Because identity and purity are separate questions, a purity percentage becomes evidence only when the method, lot number, testing laboratory, and analysis date travel with it. Those fields are the core of most peptide certificate of analysis requirements.
Sintesis Peptida Start with the method. A defensible reversed-phase HPLC-UV result names its detection wavelength, column, and gradient, and states the standard it was validated against. One contract laboratory’s published method uses a C18 5 µm, 4.6 × 250 mm column with a water/acetonitrile gradient containing 0.1% TFA or formic acid, reads primarily at 214 nm with a 280 nm secondary channel, reports impurities down to 0.1% of total peak area, and is validated to ICH Q2(R1) and USP <621> (ACS Lab Test, retrieved 2026-01-01). That is a documented HPLC method, not just a percentage. If a CoA says “≥98% (HPLC)” and stops there, you cannot tell whether the number came from a validated method or a single injection on an uncalibrated system.
The second distinction matters more than most buyers expect: a UV area-percent figure is not net peptide content by weight. USP assigns peptide purity by mass balance, measuring every detectable impurity class, including peptide-related impurities, counter ion, water, residual solvents, and non-combustible residues, and subtracting the total from 100% (USP reference standard work, 2023). Because UV area-percent purity does not measure counterions, TFA or acetate salts, water content, or residual solvents, a high area percentage can coexist with a substantially lower net peptide content by weight.
Then check the lot and the date against your own order. A purity figure belongs to one lot tested on one date, not to a product line. When you scale from milligrams to grams, ask for the CoA of the Peptida Sintetis lot you are actually receiving, and compare its analysis date to the shipping date. A CoA dated eighteen months before shipment describes a different batch of material than the one in the box.
What failure looks like: a CoA with a purity percentage, no method line, no lot-specific analysis date, and no chromatogram. You have no way to tell whether the figure was measured, estimated, or copied from a previous batch.
Melangkah 3: Request the Documentation Package and Check It Against ALCOA+
Once you know which fields a purity claim needs, the next step is to request the whole package, because a CoA is not a single document. It is a package, and the package is what you inspect.
Ask for these fields before you evaluate anything else: lot number, manufacture date, analysis date, testing laboratory, analytical method, chromatogram or trace reference, mass-spectrometry identity result, storage conditions, and an explicit statement of what was not tested. That last field is the one most suppliers omit, and its absence tells you more than its presence would. These are the core peptide certificate of analysis requirements a qualification reviewer works through.
Judge the package against the ALCOA+ data-integrity attributes, which require records to be attributable, legible, contemporaneous, original and accurate, plus complete, consistent, enduring and available. The five original attributes trace to FDA CGMP guidance finalized in December 2018; MHRA’s GxP data-integrity guidance, Revision 1 (March 2018), added the remaining four. Contemporaneous is the test that catches most weak packages: an analysis date reconstructed months after synthesis fails it.
A lot-specific package from MOL Changes illustrates the inspectable form: an analytical report tied to a named lot, with traceable quality data for research and industrial use. MOL Changes operates Class 100 ultra-sterile cleanroom production with in-house HPLC, MS and sterility testing, and manufactures custom and catalog peptides from milligrams to kilograms.
⚠️ Warning: a CoA is produced by a party with an interest in the result; independent third-party testing is what raises its evidentiary weight.
Melangkah 4: Apply Intended-Use Controls as a Qualification Criterion
Documentation tells you what was tested; intended-use controls tell you what the supplier believes the product is for. Research use only peptide labelling is not boilerplate, and treating it as boilerplate is how buyers end up qualifying a consumer-facing seller. RUO designates a product manufactured and sold for laboratory research, whether that is in vitro studies, animal testing, analytical chemistry, or preclinical investigation. Such products are not made under pharmaceutical GMP, have not undergone the testing required for human use, and carry no regulatory approval (Peptide Journal, 2025).
The label alone decides nothing. Under the FD&C Act, intended use, not the disclaimer, governs: a peptide marketed or intended for the diagnosis, cure, treatment, or prevention of disease in humans is a drug under federal law regardless of what the label says. FDA weighs labeling and packaging, advertising and marketing, and the totality of evidence (Peptide Journal, 2025).
So read the whole storefront, not the product page. A supplier that publishes dosing guidance, human-use testimonials, or before-and-after claims has told you its intended market, whatever its footer says. A supplier whose materials stay on analytical and laboratory ground has separated research-grade from consumer-facing product.
Nothing in this guide is medical or dosing guidance, and no product referenced here is offered for human use.
Melangkah 5: Test Whether the Supplier Communicates Transparently
Transparency is the criterion most suppliers fail, because it costs them something to pass. A supplier that communicates well will tell you what its documentation does not prove, name the laboratory that ran the tests, and publish dated lot records instead of a single undated purity figure.
Three pass/fail signals carry most of the weight in research-grade peptide supplier verification:
-
States the limits of its own documents. A passing supplier says plainly that a certificate of analysis (KoA) confirms identity and measured purity for one lot, and does not establish sterility, endotoxin levels, or suitability for any clinical use. A failing supplier lets the CoA imply more than it shows.
-
Names the testing laboratory. A passing supplier identifies the lab and whether it is in-house or independent. A failing supplier writes “third-party tested” with no lab named, which is a claim, not a record.
-
Publishes dated lot records. A passing supplier shows lot numbers with analysis dates you can match to your shipment. A failing supplier shows one purity number with no lot and no date.
Untuk Tip: ask for two CoAs from different lots of the same peptide and compare the impurity profiles, not just the headline purity figure.
A useful category observation: across the supplier pages reviewed for this guide, none taught readers how to read a CoA, what a passing versus failing result looks like, or how to spot a forged or duplicated CoA. The top-ranking supplier page also carried no page-level publish or update date. Treat an undated page as a signal in itself, and ask the supplier directly when the record was last updated.
Melangkah 6: Put the Five Criteria Into a Supplier Qualification Workflow
Run the five criteria as a sequence, not a checklist you sample from. Identity confirmation comes first, because a purity figure for the wrong molecule is meaningless. Purity review follows, then the documentation package, then intended-use controls, then transparency. A supplier that fails any stage is rejected at that stage; you do not carry it forward to see whether the rest looks better.
The reason to run your own sequence rather than accept a supplier’s self-reported pass rate is that the published failure figures are narrower than they appear. Third-party testing programs have published tens of thousands of results, termasuk 9,997 peptide vials submitted for analysis, of which BPC-157 accounted for 756 tests across 110 vendors (peptidesbeat.com report on the Finnrick dataset, dataset updated 2026-09-03). The widely repeated claim that roughly one in three samples fail basic expectations comes from that same single dataset, self-reported and not peer-reviewed, and the proportion has held stable over 12 ke 14 months of reporting on the gray-market peptide boom. One dataset, echoed across outlets, is not independent corroboration.
That is the case for peptide supplier due diligence as a buyer-side control. Research-grade peptide supplier verification is something you perform against artifacts you inspect, and no documentation package substitutes for it. Produksi Peptida
Common Mistakes to Avoid
Accepting a high purity figure as proof of identity. A 98% HPLC result says the main peak dominates the chromatogram; it does not say the peak is the right molecule. Identity comes from mass spectrometry, where the observed molecular weight matches the designed construct. Suppliers blur the two because a single purity number is easier to market than a two-part analytical story. Ask for both, and check that the identity method names the expected mass.
Treating a UV area-percent number as net peptide content by weight. UV detection at 214 nm responds to the peptide backbone, so the percentage reflects relative peak area, not how much peptide sits in the vial. Residual counterions, water and salts are invisible to the detector but very present on the balance. This is the most common gap in peptide certificate of analysis requirements: a UV area-percent figure is not net peptide content by weight, and a supplier who presents it as such has either misunderstood the assay or is counting on you to.
Listing assays without showing what a pass or fail looks like. Across the supplier pages reviewed for this guide, chromatograms and spectra appear as decoration rather than as results with stated acceptance criteria. A specification you cannot compare against a reported value is not a specification.
Leaving pages undated. An undated CoA or specification page cannot be tied to a lot, a method revision or a testing laboratory, which undermines the traceability the document exists to provide.
Pengambilan Kunci: a purity figure without a method, lot, laboratory and date is a claim, not a measurement.
Pertanyaan yang Sering Diajukan
How can I tell a forged or duplicated CoA from a genuine one?
Check that the lot number on the certificate matches the lot on the vial label and packing slip, then look for a chromatogram or spectrum specific to that lot rather than a figure reused across products. A document that names no testing laboratory and no analysis date, or whose chromatogram reappears under a second lot number, is unverified. Requesting the raw data file behind the report is the strongest check available. Tentang
Can I verify a supplier’s claim that a third party tested its peptides?
Partly. You can confirm the named laboratory exists, offers the cited method, and issues reports in that format. What the document cannot show is that the sample submitted came from the lot you received. That gap is not hypothetical: reporting on the gray-market peptide boom found that about a third of the thousands of products analysed failed basic quality checks, a proportion broadly unchanged over the 12 ke 14 months of data gathering. Independent testing of a retained sample from your own receipt is the only way to close it.
What should I do if a CoA reports purity with no chromatogram or lot match?
Ask for the missing artifacts before evaluating the number. A purity figure without a method, a lot identifier, and a supporting chromatogram cannot be traced to anything, so it functions as a marketing statement rather than analytical evidence. Note also what a purity figure is not: the FDA’s peptide dossier guidance sets at least one peptide-related impurity threshold of 0.10% of drug substance for impurity characterization, a characterization requirement and not an identity proof. Meeting your peptide certificate of analysis requirements means holding identity, kemurnian, and lot traceability as separate records, not one headline percentage.
Does a research-use-only label change a supplier’s legal position?
It shifts the framing rather than settling the question. A research-use-only label states the product’s intended application, and regulators assess the supplier’s conduct against that intent. As one legal analysis of the gray area puts it, intended use, not the disclaimer, governs. In practice, research use only peptide labelling is a qualification signal: a supplier that consistently separates research-grade material from consumer-facing product, and publishes no dosing or human-use guidance, is easier to qualify than one whose marketing contradicts its own label. This is not legal advice; consult counsel for your jurisdiction.
Conclusion
The five criteria are one habit: separate identity from purity, read every purity claim for its method, lot, lab and date, check the documentation package against ALCOA+, treat intended-use controls as a qualification gate, and watch how the supplier answers an awkward question. Peptide supplier due diligence is not a one-time audit but the practice of preferring a supplier whose artifacts can be inspected over one whose claims can only be believed. A lot-specific CoA that names the testing laboratory, the analytical method and the analysis date gives you something to file, compare across batches and hand to a colleague; a purity percentage with none of that context gives you nothing to check.
If you want to run the framework against a real package, request a sample CoA package or talk to a technical specialist. Both are low-commitment steps that let you test the documentation before any purchasing decision.
Disclosure: MOL Changes has a commercial interest in peptide quality standards and supplies research-grade peptides with lot-specific analytical documentation. Nothing in this guide is medical or dosing guidance, and all products discussed are for research use only.
Reviewed by the MOL Changes technical team. Consult a qualified professional before making decisions about research materials.
